Immunotherapy for Guillain-Barré syndrome: A systematic review

Brain

Volumn 130, Issue 9, 2007, Pages 2245-2257

  Hughes, Richard A C ^a   Swan, Anthony V ^a   Raphaël, Jean Claude ^b   Annane, Djillali ^b   Van Koningsveld, Rinske ^c   Van Doorn, Pieter A ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Corticosteroid; Guillain Barr syndrome; Intravenous immunoglobulin; Plasma exchange; Systematic review; Treatment

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE;

BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; GUILLAIN BARRE SYNDROME; HEART ARRHYTHMIA; HUMAN; IMMUNOADSORPTION; IMMUNOTHERAPY; INFECTION; LUNG EMBOLISM; MUSCLE STRENGTH; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WALKING;

DISABILITY EVALUATION; GLUCOCORTICOIDS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34548228508     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm004     Document Type: Review

References (56)

1. Annane D, Gunn A, Hughes RAC, Jewitt KM, Miller RG, Morve D, et al. Neuromuscular Disease Group, Chichester, UK: John Wiley & Sons, Ltd; 2004.
2. Bansal BC, Sood AK, Gupta AK, Yadav P. Role of steroids in the treatment of Guillain-Barré syndrome - a controlled trial. Neurol India 2004; 34: 329-35.
3. Bensa S, Hadden RDM, Hahn A, Hughes RAC, Willison HJ. Randomised controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome. Eur J Neurol 2000; 7: 423-6.
4. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet 1978; 2: 1100.
5. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996; 46: 100-3.
6. Bromberg MB, Carter O. Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data. Muscle Nerve 2004; 30: 20-37.
7. Consensus Conference. The utility of therapeutic plasmapheresis for neurological disorders. Statement. JAMA 1986; 256: 1333-7.
8. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004; 291: 2367-75.
9. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003; 60: 1736-7.
10. Diener HC, Haupt WF, Kloss TM, Rosenow F, Philipp T, Koeppon S, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol 2001; 46: 107-9.
11. Farkkila M, Kinnlinen E, Haapanen E, Inanainen M. Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 1987; 37: 837-40.
12. French Cooperative group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.
13. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992; 32: 94-97.
14. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41: 298-306.
15. García AC, Vidal BE, Rebolledo A, Texeira F, Ordaz FA, Futrán YJ. Treatment of the acute phase of Guillain-Barré-Strohl syndrome with megadosis of methylprednisolone. Rev Invest Clín (Méx) 1985; 37: 119-24.
16. Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol 2001; 14: 605-13.
17. Greenwood RJ, Newsom Davis JM, Hughes RAC, Aslan S, Bowden AN, Chadwick DW, et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 1: 877-9.
18. Griffin JW, Li CY, Ho TW, Xue P, Macho C, Gao CY, et al. Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 1995; 118: 577-95.
19. Guillain-Barré Syndrome Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993; 341: 586-90.
20. Gürses N, Uysal S, Cetinkaya F, Icslek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995; 27: 241-3.
21. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 1996; 137: 145-9.
22. Hughes RAC. Treatment of Guillain-Barré syndrome. Heidelberg: Springer; 1990.
23. Hughes RAC. Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit? Lancet 2004; 363: 181-2 [correction at Lancet 2004; 363: 1328].
24. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366: 1653-66.
25. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2: 750-3.
26. Hughes RAC, Raphaël J-C, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006a; CD002063.
27. Hughes RAC, Swan AV, van KR, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2006b; CD001446.
28. Jacobs BC, van Doorn PA, Schmitz P, Tio-Gillen AP, Herbrink P, Visser LH, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996; 40: 181-7.
29. Kanra G, Ozon A, Vajsar J, Castagna L, Secmeer G, Topaloglu H. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol 1997; 1: 7-12.
30. Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apheresis 2001; 16: 130-3.
31. Kleyweg RP, van der Meché FGA, Meulstee J. Treatment of Guillain-Barré Syndrome with high dose gammaglobulin. Neurology 1988; 38: 1639-42.
32. Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991; 14: 1103-9.
33. Korinthenberg R, Schessl J, Kirschner J, Möntning JS. Intravenous immunoglobulin in the treatment of childhood Guillain-Barré syndrome. Pediatrics 2005; 116: 8-14.
34. Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N. Indicators of rapid clinical recovery in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatr 2001; 70: 560-2.
35. Mendell JR, Kissel JT, Kennedy MS, Sahenk Z, Grinvalsky HT, Pittman GL, et al. Plasma exchange and prednisone in Guillain-Barré syndrome. A controlled randomised trial. Neurology 1985; 35: 1551-5.
36. Nomura T, Hamaguchi K, Hattori T, Satou T, Mannen T, et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol Therapeutics 2000; 18: 69-81.
37. Osterman PO, Lundemo G, Pirskanen R, et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296-9.
38. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
39. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutten IJ, Swan AV, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 2003; 61: 1282-4.
40. Raphaël J-C, Chevret S, Harboun M, Jars-Guincestre MC. French Guillain-Barré Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatr 2001; 71: 235-8.
41. Raphaël JC, Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2002; CD001798.
42. Shukla SK, Agarwal R, Gupta OP, Pande G, Mamta S. Double blind control trial of prednisolone in Guillain-Barré syndrome - a clinical study. Clinician - India 1988; 52: 128-34.
43. Singh NK, Gupta A. Do corticosteroids influence the disease course or mortality in Guillain-Barré syndrome. J Assoc Physicians India 1996; 44: 22-4.
44. Stillman JS, Ganong WF. The Guillain-Barré syndrome: report of a case treated with ACTH and cortisone. New Engl J Med 1952; 246: 293-6.
45. Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976; 26: 205-12.
46. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35: 1096-104.
47. van der Meché FGA, Schmitz PIM, Guillain-Barré Dutch. Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med 1992; 326: 1123-9.
48. van Koningsveld R, Schmitz PIM, van der Meché FGA for the Dutch GBS Study Group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363: 192-6.
49. van Koningsveld R, van Doorn PA, Schmitz PI, Ang CW, Van, der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 2000; 54: 620-5.
50. Wang R, Feng A, Sun W, Wen Z. Intravenous immunoglobulin in children with Guillain-Barré syndrome. J Appl Clin Pediatr 2001; 16: 223-4.
51. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125: 2591-625.
52. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatr 1988; 51: 605-12.
53. Wollinsky KH, Hulser PJ, Brinkmeier H, Aulkemeyer P, Bossenecker W, Huber-Hartmann KH, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology 2001; 57: 774-80.
54. Yuki N, Ang CW, Koga M, Jacobs BC, van Doom PA, Hirata K, et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol 2000; 47: 314-21.
55. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA 2004; 101: 11404-9.
56. Zhang X, Xia J, Ye H. Effect of tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barré syndrome. Chung-Kuo Chung Hsi Chieh Ho Tsa Chih 2000; 20: 332-4.